Talima Therapeutics, a Santa Clara, Calif., developer of techniques that limit drug delivery to specific parts of the body, raised $19 million in a second funding round. The company’s release is here.

The company is at work on localized drug-delivery techniques that could serve as alternatives to systemic drugs, potentially improving their effectiveness while limiting side effects. Its initial focus lies in dermatology, a field in which “local application” — that is, ointments, creams and lotions — is already in common practice. Talima hasn’t revealed much about its technology beyond describing it as a “micro-implant” system, which could mean almost anything. The new funding will carry its leading drug candidates — whatever they are — into mid-stage human testing.

The round was led by US Venture Partners and Latterell Venture Partners, joined by current investors De Novo Ventures and Palo Alto Healthcare.